ProQR Therapeutics NV (NASDAQ:PRQR) Receives Consensus Recommendation of “Buy” from Brokerages

ProQR Therapeutics NV (NASDAQ:PRQR) has been assigned an average recommendation of “Buy” from the nine brokerages that are presently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and seven have assigned a buy recommendation to the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $30.40.

A number of research analysts recently issued reports on the company. ValuEngine upgraded ProQR Therapeutics from a “hold” rating to a “buy” rating in a report on Wednesday. BidaskClub downgraded ProQR Therapeutics from a “sell” rating to a “strong sell” rating in a report on Wednesday, July 3rd. Finally, Zacks Investment Research upgraded ProQR Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, July 10th.

Shares of NASDAQ PRQR traded down $0.69 during midday trading on Friday, reaching $8.70. The company had a trading volume of 3,375 shares, compared to its average volume of 207,596. ProQR Therapeutics has a one year low of $6.75 and a one year high of $24.00. The company has a debt-to-equity ratio of 0.14, a quick ratio of 10.08 and a current ratio of 10.08. The company’s fifty day simple moving average is $9.31. The company has a market cap of $346.36 million, a PE ratio of -6.86 and a beta of 0.11.

ProQR Therapeutics (NASDAQ:PRQR) last announced its quarterly earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.05). As a group, research analysts anticipate that ProQR Therapeutics will post -1.65 earnings per share for the current fiscal year.

A number of large investors have recently made changes to their positions in PRQR. Northern Trust Corp purchased a new stake in shares of ProQR Therapeutics in the 4th quarter worth approximately $666,000. Nikko Asset Management Americas Inc. purchased a new position in ProQR Therapeutics in the first quarter worth about $4,016,000. Altrinsic Global Advisors LLC grew its position in ProQR Therapeutics by 9.8% in the first quarter. Altrinsic Global Advisors LLC now owns 199,060 shares of the biopharmaceutical company’s stock worth $2,761,000 after acquiring an additional 17,700 shares in the last quarter. Geode Capital Management LLC grew its position in ProQR Therapeutics by 14.1% in the fourth quarter. Geode Capital Management LLC now owns 19,193 shares of the biopharmaceutical company’s stock worth $302,000 after acquiring an additional 2,375 shares in the last quarter. Finally, Legal & General Group Plc purchased a new position in ProQR Therapeutics in the fourth quarter worth about $1,057,000. Institutional investors own 61.70% of the company’s stock.

About ProQR Therapeutics

ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. Its lead product candidates include eluforsen, a RNA-based oligonucleotide used for the treatment of cystic fibrosis; QR-110, an oligonucleotide that is designed to treat Leber's congenital amaurosis; QR-313, a dermatology candidate for the treatment of epidermolysis bullosa; and QR-421a and QR-411 to treat type 2A Usher syndrome.

See Also: How to calculate compound interest

Analyst Recommendations for ProQR Therapeutics (NASDAQ:PRQR)

Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.